Financial Performance - The company's operating revenue for Q3 2023 was ¥518,193,841.85, a decrease of 9.89% compared to the same period last year[9]. - The net profit attributable to shareholders for Q3 2023 was ¥134,354,740.37, down 19.96% year-over-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥116,215,968.02, reflecting a decline of 30.29% compared to the previous year[9]. - The basic earnings per share for Q3 2023 was ¥0.31, a decrease of 18.42% year-over-year[9]. - The net profit for the current period is 404,300,300.32, a decrease of 11.21% compared to 455,464,130.48 in the previous period[25]. - The total profit for the current period is 410,937,602.33, down from 470,876,510.39, reflecting a decline of 12.74%[25]. Assets and Liabilities - The total assets at the end of the reporting period were ¥6,687,316,163.11, an increase of 12.22% from the end of the previous year[9]. - Total liabilities increased to ¥3,544,922,736.07 from ¥3,156,510,196.83, indicating a rise in financial obligations[22]. - Non-current assets totaled ¥3,964,912,199.91, up from ¥3,515,923,309.87, showing growth in long-term investments[22]. - The company reported a significant increase of 95.55% in non-current liabilities due within one year, reaching 366,484,790.85[35]. - As of September 30, 2023, total current assets increased to CNY 2,722,403,963.20 from CNY 2,443,097,518.10 at the beginning of the year, representing an increase of approximately 11.4%[44]. - The total liabilities and equity increased to CNY 6,687,316,163.11 from CNY 5,959,020,827.97, an increase of about 12.2%[52]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥30,495,061.60, down 62.89% year-over-year[9]. - The net cash flow from operating activities for the period was CNY 30,495,061.60, down from CNY 82,185,693.73, a decrease of about 62.9%[49]. - Cash and cash equivalents decreased by 42.42% to 447,576,764.85 from 777,248,693.86 due to operational payments[35]. - Cash and cash equivalents at the end of the period stood at CNY 343,961,158.86, down from CNY 745,156,143.63, a decrease of approximately 53.8%[56]. - The company reported a net cash outflow from investing activities of CNY 629,625,927.07, compared to CNY 927,651,069.29 in the previous period[56]. Shareholder Information - The equity attributable to shareholders at the end of the reporting period was ¥3,142,393,427.04, up 12.13% compared to the previous year[9]. - The company reported a total of 30,248 common shareholders at the end of the reporting period[13]. - The company’s total equity attributable to shareholders increased to CNY 3,142,393,427.04 from CNY 2,802,510,631.14, an increase of about 12.1%[52]. Expenses and Costs - Total operating costs increased to ¥968,931,149.46, up 7.5% from ¥901,021,185.54 in the same period last year[24]. - Research and development expenses were ¥229,840,778.19, a decrease of 11.0% compared to ¥258,238,348.53 in the previous year[24]. - Financial expenses decreased significantly to ¥27,538,223.59 from ¥63,728,301.67, reflecting a reduction in interest expenses[24]. - Operating costs rose by 36.67% to 437,659,600.24 from 320,226,712.60, driven by increases in material and labor costs[35]. Government Subsidies and Other Income - The company received government subsidies amounting to ¥21,061,443.49 during the reporting period[9]. - Other income increased to ¥57,916,312.67, compared to ¥21,147,279.58 in the previous year, indicating improved financial performance[24]. - Other income surged by 173.87% to 57,916,312.67 from 21,147,279.58, attributed to increased government subsidies[35]. Future Plans - The company plans to continue expanding its market presence and investing in new product development to drive future growth[23]. - The company plans to repurchase 688,800 shares of restricted stock at a price of 23.782 per share, totaling 16,381,041.60[43].
普利制药(300630) - 2023 Q3 - 季度财报